News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,984 Results
Type
Article (44257)
Company Profile (313)
Press Release (706394)
Multimedia
Podcasts (129)
Webinars (22)
Section
Business (211199)
Career Advice (2116)
Deals (36816)
Drug Delivery (141)
Drug Development (83567)
Employer Resources (176)
FDA (16923)
Job Trends (15538)
News (357865)
Policy (34169)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2640)
Accelerated approval (47)
Adcomms (28)
Allergies (177)
Alliances (51589)
ALS (214)
Alzheimer's disease (1816)
Antibody-drug conjugate (ADC) (456)
Approvals (17298)
Artificial intelligence (686)
Autoimmune disease (293)
Automation (57)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (226)
Biotechnology (188)
Bladder cancer (187)
Brain cancer (75)
Breast cancer (757)
Cancer (5871)
Cardiovascular disease (483)
Career advice (1802)
Career pathing (43)
CAR-T (335)
CDC (59)
Celiac Disease (3)
Cell therapy (912)
Cervical cancer (47)
Clinical research (72399)
Collaboration (2111)
Company closure (5)
Compensation (1397)
Complete response letters (87)
COVID-19 (2815)
CRISPR (113)
C-suite (1146)
Cystic fibrosis (157)
Data (7887)
Decentralized trials (3)
Denatured (38)
Depression (165)
Dermatology (86)
Diabetes (593)
Diagnostics (7015)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (327)
Drug pricing (219)
Drug shortages (34)
Duchenne muscular dystrophy (287)
Earnings (93829)
Editorial (69)
Employer branding (21)
Employer resources (155)
Events (122471)
Executive appointments (1108)
FDA (20675)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1735)
Gene editing (240)
Generative AI (59)
Gene therapy (741)
GLP-1 (1103)
Government (4875)
Grass and pollen (7)
Guidances (409)
Healthcare (19181)
HIV (79)
Huntington's disease (57)
IgA nephropathy (99)
Immunology and inflammation (301)
Immuno-oncology (94)
Indications (192)
Infectious disease (3153)
Inflammatory bowel disease (224)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (293)
Interviews (330)
IPO (16945)
IRA (57)
Job creations (4075)
Job search strategy (1500)
JPM (65)
Kidney cancer (19)
Labor market (99)
Layoffs (592)
Leadership (41)
Legal (8430)
Liver cancer (100)
Longevity (33)
Lung cancer (768)
Lymphoma (432)
Machine learning (62)
Management (60)
Manufacturing (1075)
MASH (192)
Medical device (14013)
Medtech (14134)
Mergers & acquisitions (21113)
Metabolic disorders (1535)
mRNA (216)
Multiple sclerosis (187)
NASH (18)
Neurodegenerative disease (419)
Neuropsychiatric disorders (109)
Neuroscience (3348)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4578)
Now hiring (78)
Obesity (723)
Opinion (312)
Ovarian cancer (220)
Pain (270)
Pancreatic cancer (301)
Parkinson's disease (360)
Partnered (34)
Patents (601)
Patient recruitment (673)
Peanut (65)
People (61621)
Pharmaceutical (85)
Pharmacy benefit managers (34)
Phase 1 (22469)
Phase 2 (31858)
Phase 3 (23855)
Pipeline (8742)
Policy (332)
Postmarket research (2659)
Preclinical (9596)
Press Release (68)
Prostate cancer (300)
Psychedelics (57)
Radiopharmaceuticals (328)
Rare diseases (1108)
Real estate (6320)
Recruiting (72)
Regulatory (26304)
Reports (57)
Research institute (2463)
Resumes & cover letters (362)
Rett syndrome (39)
RNA editing (23)
RSV (88)
Schizophrenia (185)
Series A (294)
Series B (215)
Service/supplier (11)
Sickle cell disease (115)
Special edition (26)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3790)
State (2)
Stomach cancer (19)
Supply chain (128)
Tariffs (99)
The Weekly (88)
Vaccines (1119)
Venture capital (109)
Weight loss (476)
Women's health (126)
Worklife (20)
Date
Today (190)
Last 7 days (887)
Last 30 days (3653)
Last 365 days (30725)
2026 (12544)
2025 (30677)
2024 (35760)
2023 (40626)
2022 (51797)
2021 (56328)
2020 (54789)
2019 (47397)
2018 (35768)
2017 (33135)
2016 (32663)
2015 (38615)
2014 (32526)
2013 (27658)
2012 (29754)
2011 (30511)
2010 (28506)
Location
Africa (806)
Alabama (93)
Alaska (7)
Arizona (355)
Arkansas (16)
Asia (42602)
Australia (6840)
California (13317)
Canada (3784)
China (1375)
Colorado (569)
Connecticut (577)
Delaware (407)
Europe (91813)
Florida (1989)
Georgia (424)
Hawaii (3)
Idaho (62)
Illinois (1070)
India (93)
Indiana (608)
Iowa (23)
Japan (548)
Kansas (132)
Kentucky (50)
Louisiana (42)
Maine (76)
Maryland (1595)
Massachusetts (9538)
Michigan (365)
Minnesota (721)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3499)
New Mexico (30)
New York (3483)
North Carolina (1705)
North Dakota (9)
Northern California (6666)
Ohio (398)
Oklahoma (24)
Oregon (46)
Pennsylvania (2681)
Puerto Rico (29)
Rhode Island (50)
South America (1179)
South Carolina (86)
South Dakota (2)
Southern California (5252)
Tennessee (210)
Texas (2114)
United States (47063)
Utah (396)
Vermont (1)
Virginia (338)
Washington D.C. (80)
Washington State (1066)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
750,984 Results for "amarin pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amarin Reports 2026 First Quarter Financial Results
April 29, 2026
·
18 min read
Press Releases
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
April 15, 2026
·
2 min read
Press Releases
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
·
17 min read
Press Releases
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
March 18, 2026
·
15 min read
Press Releases
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
February 11, 2026
·
2 min read
Press Releases
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
January 8, 2026
·
11 min read
Press Releases
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
February 23, 2026
·
11 min read
Press Releases
Amarin Reports Third Quarter 2025 Financial Results
October 29, 2025
·
17 min read
Press Releases
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
January 9, 2026
·
13 min read
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
1 of 75,099
Next
